Most Read Articles
17 Nov 2014
The methodological quality of clinical practice guidelines for myasthenia gravis (MG) remains uncertain. Thus, an evaluation on these guidelines was conducted.
12 Oct 2014
Recent studies showed that rituximab is an effective treatment for myasthenia gravis but only limited data were available. Thus, a review on its efficacy and safety was conducted in this study.
01 Jun 2015
According to an English study, cell-based assay shows efficacy in the diagnosis of radioimmunoprecipitation assay (RIPA)-negative myasthenia gravis, especially in children.
09 May 2016
Autologous hematopoietic stem cell transplant (HSCT) provides long-term symptom- and treatment-free remission in patients with severe myasthenia gravis (MG), a retrospective cohort study has shown.

Perfusion predict time to progression in glioblastoma

01 Aug 2017

Positive perfusion in surgical cavity wall enhancement (SCWE) may predict longer time to progression (TTP) in glioblastoma patients, a new study suggests.

The study included 60 glioblastoma patients receiving standard concurrent chemoradiation therapy (CCRT) after surgery. Exclusion criteria included magnetic resonance (MR) imaging performed more than 1 month after CCRT, no follow-up MR imaging and poor quality of arterial spin labelling (ASL) imaging.

Two readers independently assessed the SCWE for perfusions (positive or negative), contrast-enhancing lesions (presence or absence) and contrast enhancement pattern (nodular or non-nodular). Perfusion fraction was calculated by dividing areas of high perfusion by areas of contrast enhancement.

Univariate analysis showed that positive perfusion was significantly associated with longer TTP (hazard ratio [HR], 0.49; 95 percent CI, 0.25 to 0.96; p=0.04). Perfusion fraction with a higher volume was also associated with longer TTP for both reader 1 (HR, 0.98; 0.98 to 0.99; p=0.021) and 2 (HR, 0.98; 0.98 to 0.99; p=0.005).

Subsequent multivariable analysis showed that positive perfusion (HR, 0.33; 0.15 to 0.68; p=0.02) and a high perfusion fraction (HR, 0.97; 0.97 to 0.99; p=0.001 for reader 1 and HR, 0.98; 0.97 to 0.99; p<0.001 for reader 2) were both significant independent predictors of longer TTP.

Kaplan-Meier analysis showed that those with increased perfusion had significantly longer median TTP compared with those with decreased perfusion (29 vs 13 months; p=0.036).

Moreover, linear regression showed that perfusion fraction was significantly correlated with TTP for both readers (p<0.001 for both).

Editor's Recommendations
Most Read Articles
17 Nov 2014
The methodological quality of clinical practice guidelines for myasthenia gravis (MG) remains uncertain. Thus, an evaluation on these guidelines was conducted.
12 Oct 2014
Recent studies showed that rituximab is an effective treatment for myasthenia gravis but only limited data were available. Thus, a review on its efficacy and safety was conducted in this study.
01 Jun 2015
According to an English study, cell-based assay shows efficacy in the diagnosis of radioimmunoprecipitation assay (RIPA)-negative myasthenia gravis, especially in children.
09 May 2016
Autologous hematopoietic stem cell transplant (HSCT) provides long-term symptom- and treatment-free remission in patients with severe myasthenia gravis (MG), a retrospective cohort study has shown.